What Actually Triggers a Competent Authority Inspection

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Many manufacturers believe that once a Notified Body has approved their technical documentation, the clinical evaluation is essentially settled. The device is CE marked, the market surveillance period begins, and attention shifts to post-market activities.

But competent authorities operate on a different timeline and with a different mandate.

While Notified Bodies assess conformity for the purposes of certification, competent authorities assess compliance for the purposes of market surveillance and enforcement. The clinical evaluation that satisfied a Notified Body may not satisfy a competent authority conducting an unannounced inspection two years later.

Understanding what triggers these inspections is not about predicting the future. It is about recognizing the patterns that draw regulatory scrutiny and ensuring your clinical evaluation can withstand examination outside the certification process.

The Two Types of Triggers

Competent authority inspections of clinical evaluation fall into two broad categories: reactive triggers and proactive triggers.

Reactive triggers are event-driven. Something happens in the field, in the literature, or in another jurisdiction that raises concern about a device or device category. The competent authority responds by examining the clinical basis for the device’s safety and performance claims.

Proactive triggers are surveillance-driven. The competent authority conducts routine sampling inspections across device types, manufacturers, or therapeutic areas to assess the quality of clinical evaluation practices in the market.

Both types lead to the same inspection process, but the initial focus differs.

Reactive Triggers: What Draws Immediate Attention

The most common reactive trigger is a serious incident or field safety corrective action (FSCA) that suggests a gap between the clinical evidence base and real-world performance.

When a manufacturer initiates an FSCA, the competent authority reviews the incident reports, the root cause analysis, and the justification for the corrective action. If the incident reveals a risk that should have been anticipated or mitigated based on the clinical evaluation, an inspection may follow.

The question the competent authority asks is simple: did the clinical evaluation adequately assess this risk before the device entered the market?

If the answer is unclear, they will inspect the clinical evaluation report, the risk management file, and the post-market data to determine whether the issue reflects a clinical evaluation deficiency.

Another reactive trigger is emerging clinical evidence that contradicts the safety or performance claims in the device’s technical documentation.

This can come from new publications showing higher complication rates than reported in the clinical evaluation, from systematic reviews that challenge the validity of the equivalence claim, or from real-world evidence databases that reveal usage patterns inconsistent with the intended purpose.

Competent authorities monitor scientific literature, registers, and post-market databases. When new evidence surfaces that raises doubt about a device’s clinical basis, they may inspect the clinical evaluation to determine whether the manufacturer is aware of the evidence and whether it has been appropriately integrated into the ongoing evaluation.

A third reactive trigger is cross-border intelligence sharing.

Under the MDR, competent authorities across EU member states exchange information about devices under scrutiny, inspections conducted, and deficiencies identified. If one competent authority inspects a manufacturer’s clinical evaluation and finds significant issues, other member states may initiate their own inspections of related devices or device families from the same manufacturer.

This is particularly relevant for manufacturers with multiple CE marks across different member states. A deficiency identified in one clinical evaluation can trigger broader scrutiny of the manufacturer’s clinical evaluation practices.

Proactive Triggers: Surveillance Sampling and Risk Profiling

Proactive inspections are less predictable but follow identifiable patterns.

Competent authorities conduct routine surveillance inspections across device categories, often targeting high-risk devices, new market entrants, or device types with a history of clinical evaluation deficiencies.

Class III and implantable Class IIb devices are inspected more frequently than Class IIa devices. This reflects both the higher risk profile and the regulatory expectation that these devices should have robust clinical investigation data rather than relying solely on equivalence.

Manufacturers entering the market for the first time, or manufacturers newly certified under the MDR after transitioning from the MDD, are also more likely to be selected for proactive inspection. The competent authority wants to verify that the clinical evaluation meets current expectations and that the manufacturer understands the MDR requirements.

Another proactive trigger is the device type or therapeutic area.

Certain device categories attract more regulatory attention due to historical compliance issues or emerging safety concerns. Aesthetic devices, orthopedic implants, cardiovascular stents, and software as a medical device have all been subject to focused surveillance campaigns in recent years.

If your device falls into a category currently under scrutiny, the likelihood of a proactive inspection increases regardless of your individual compliance record.

What Competent Authorities Look for During the Inspection

Once an inspection is triggered, the competent authority will focus on specific elements of the clinical evaluation.

The first area of examination is the clinical evaluation report itself. Is it current? Does it reflect all available clinical data? Has it been updated based on post-market surveillance findings?

Under MDR Article 61(11), the clinical evaluation and its documentation must be actively updated throughout the device’s lifecycle. A clinical evaluation report that has not been revised since the initial certification will raise immediate concern.

The second area is the appraisal of clinical data. How was the literature search conducted? Were all relevant studies identified? How were studies selected for inclusion or exclusion? Was the appraisal method rigorous and transparent?

Competent authorities increasingly scrutinize the literature review methodology. A cursory PubMed search with limited date ranges or poorly defined search strings will not withstand inspection.

The third area is equivalence claims. If the device relies on equivalence to another device, the competent authority will assess whether the equivalence claim is valid, whether the equivalent device has a sound clinical evidence base, and whether any differences between the devices have been adequately addressed.

Equivalence remains one of the most frequently cited deficiencies in competent authority inspections. Manufacturers often underestimate the rigor required to demonstrate equivalence under the MDR.

The fourth area is the integration of post-market data into the clinical evaluation. Has the PMCF plan been executed? Are PMCF data being fed back into the clinical evaluation report? Are trends in complaints, incidents, or adverse events being analyzed for clinical significance?

A PMCF plan that exists only on paper, with no evidence of execution or data integration, signals to the competent authority that the clinical evaluation is not truly ongoing.

How to Reduce the Likelihood of a Triggered Inspection

You cannot eliminate the possibility of a competent authority inspection. Proactive surveillance is random by design, and reactive triggers are often outside your control.

But you can reduce the factors that make your device a higher-probability target.

First, ensure that your clinical evaluation is genuinely updated throughout the device’s lifecycle. This means scheduled updates even when no significant new data emerges, and unscheduled updates whenever post-market data, new literature, or incident trends require reassessment.

A clinical evaluation that is clearly living and evolving sends a strong signal of compliance.

Second, maintain a robust and transparent PMCF program. Execute the PMCF plan as written. Collect and analyze the data. Feed the findings back into the clinical evaluation report. Document all of this clearly.

Competent authorities view PMCF execution as a proxy for the manufacturer’s overall commitment to post-market vigilance.

Third, monitor emerging clinical evidence actively. Do not wait for the competent authority to identify new studies that challenge your device’s clinical basis. Proactively appraise new literature, assess its relevance, and integrate it into your clinical evaluation.

If new evidence raises concerns, address them transparently in the clinical evaluation report. Explain how the findings do or do not affect your device’s risk-benefit profile.

Fourth, scrutinize your equivalence claims with the same rigor a competent authority would apply. If your equivalence claim is based on weak technical or clinical similarity, or if the equivalent device has a limited evidence base, consider whether you need additional clinical data to strengthen your own clinical evaluation.

Fifth, respond to FSCAs and serious incidents with a clinical evaluation lens. When an incident occurs, do not limit your analysis to the immediate technical cause. Ask whether the incident reveals a gap in the clinical evaluation, and if so, update the clinical evaluation report accordingly.

This proactive approach demonstrates to the competent authority that you are using post-market data to refine your understanding of the device’s clinical profile.

What Happens If You Are Inspected

If a competent authority initiates an inspection of your clinical evaluation, they will typically request access to the clinical evaluation report, the technical documentation, the PMCF plan and data, risk management files, and any relevant post-market surveillance records.

The inspection may be conducted on-site or remotely, depending on the competent authority’s procedures and the scope of the inspection.

During the inspection, inspectors will ask detailed questions about how the clinical evaluation was conducted, how data were appraised, how equivalence was demonstrated, and how post-market data are being integrated.

They will look for consistency between the clinical evaluation report, the instructions for use, the risk management file, and the post-market surveillance documentation.

If deficiencies are identified, the competent authority will issue findings and may require corrective actions. In severe cases, they may suspend or withdraw the device’s CE marking, restrict its use, or require additional clinical investigation before the device can remain on the market.

The best defense is a clinical evaluation that was conducted rigorously from the start and maintained actively throughout the device’s lifecycle.

Final Reflection

Competent authority inspections of clinical evaluation are not anomalies. They are a standard component of post-market surveillance under the MDR.

What triggers them varies, but the underlying logic is consistent: competent authorities are verifying that the clinical evidence supporting your device’s safety and performance claims is sound, current, and complete.

The clinical evaluation that satisfied a Notified Body at certification is only the beginning. The real test comes later, when a competent authority examines the same file with fresh eyes, informed by post-market data, emerging evidence, and cross-border intelligence.

The manufacturers who pass that test are the ones who treated the clinical evaluation as a continuous process, not a one-time deliverable.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.